Long-Term Weight Change after Initiating Second-Generation Antidepressants
1
Group Health Research Institute, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA
2
University of Washington, UW Tower, 15th Floor, 4333 Brooklyn Ave NE, Seattle, WA 98105, USA
3
Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Academic Editor: Nuri B. Farber
J. Clin. Med. 2016, 5(4), 48; https://doi.org/10.3390/jcm5040048
Received: 31 December 2015 / Revised: 1 April 2016 / Accepted: 6 April 2016 / Published: 13 April 2016
(1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two years among adult patients with a new antidepressant treatment episode between January, 2006 and October, 2009 in a large health system in Washington State. Medication use, encounters, diagnoses, height, and weight were collected from electronic databases. We modeled change in weight and BMI at two years after initiation of treatment using inverse probability weighted linear regression models that adjusted for potential confounders. Fluoxetine was the reference treatment; (3) Results: In intent-to-treat analyses, non-smokers who initiated bupropion treatment on average lost 7.1 lbs compared to fluoxetine users who were non-smokers (95% CI: −11.3, −2.8; p-value < 0.01); smokers who initiated bupropion treatment gained on average 2.2 lbs compared to fluoxetine users who were smokers (95% CI: −2.3, 6.8; p-value = 0.33). Changes in weight associated with all other antidepressant medications were not significantly different than fluoxetine, except for sertraline users, who gained an average of 5.9 lbs compared to fluoxetine users (95% CI: 0.8, 10.9; p-value = 0.02); (4) Conclusion: Antidepressant drug therapy is significantly associated with long-term weight change at two years. Bupropion may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications.
View Full-Text
Keywords:
obesity; antidepressant; depression; adverse effects; weight gain
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
Supplementary (DOCX, 19 KiB)
MDPI and ACS Style
Arterburn, D.; Sofer, T.; Boudreau, D.M.; Bogart, A.; Westbrook, E.O.; Theis, M.K.; Simon, G.; Haneuse, S. Long-Term Weight Change after Initiating Second-Generation Antidepressants. J. Clin. Med. 2016, 5, 48.
AMA Style
Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, Simon G, Haneuse S. Long-Term Weight Change after Initiating Second-Generation Antidepressants. Journal of Clinical Medicine. 2016; 5(4):48.
Chicago/Turabian StyleArterburn, David; Sofer, Tamar; Boudreau, Denise M.; Bogart, Andy; Westbrook, Emily O.; Theis, Mary K.; Simon, Greg; Haneuse, Sebastien. 2016. "Long-Term Weight Change after Initiating Second-Generation Antidepressants" J. Clin. Med. 5, no. 4: 48.
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit